Aim: To describe a case of autologous stem cell transplantation (ASCT) and successful engraftment in a human immunodeficiency virus (HIV) patient with lymphoma while continuing anti-retroviral treatment (ART). Clinical Case: A 55-year-old man was admitted for LACE (lomustine, etoposide, cytarabine and cyclophosphamide) ASCT for anaplastic large cell non-Hodgkin lymphoma, initially treated with CHO(E)P (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) chemotherapy. Medical history included HIV (CD4 count 329 cells per/lL and suppressed viral load for last 10 years) and doxorubicin-induced cardiotoxicity. After a complete remission demonstrated on positron emission tomography (PET) scan and bone marrow biopsy, it was decided to proceed to ASCT to consolidate treatment. Pre-existing regimen of raltegravir and emtricitabine/tenofovir was continued and full dose conditioning regimen LACE was utilised. Post-ASCT complications included culture positive Enterobacter and Enterococcal neutropenic hypotensive septicaemia and Clostridium difficile diarrhoea. After a nadir of 0.0 9 10 9 /L, neutrophils recovered to 0.86 9 10 9 /L on day 16. Outcome: Engraftment was successful, with neutrophils at >1.0 9 10 9 /L and all complications had resolved by day 30 post-transplant. At 6 months follow-up, CD4 count dropped to 201.6 cells per/lL and viral load remained stable. Conclusion: ASCT, with full-dose conditioning, can be performed while ART therapy continues, with no adverse impact on engraftment or HIV control.
INTRODUCTION
Autologous stem cell transplantation (ASCT) for relapsed acquired immunodeficiency syndrome (AIDS)-related lymphoma is a suitable treatment option; however, it is associated with a higher risk of treatment-related toxicity. A main concern is a higher rate of early non-relapse mortality (NRM). This is related to the risk of significant and prolonged post-transplant CD4 count reduction with consequent development of severe infection. [1] [2] [3] [4] [5] There is also the potential for drug interactions and overlapping side-effect profiles between the antiretrovirals (ART) and the chemotherapy agents. In the past, given these concerns, some centres have omitted and/or dose reduced one or more components of the ART and/or chemotherapy agents prior to transplant. [6] [7] [8] [9] [10] Recent data suggest that combining a standard chemotherapy conditioning regimen and maintaining suitable ART is a safe treatment approach with a good rate of lymphoma treatment response without significant increase in treatment-related toxicity. 8 Under these circumstances, patients with well-controlled HIV have had comparable outcomes to non-HIV patients. 4, 11 Maintaining low viral load (VL) with ART has been postulated to aid hastened haematopoietic recovery post-transplant by reducing the myelosuppressive burden of HIV on the bone marrow. days -4, -3, -2) is a conditioning regimen which can be used in ASCT for lymphoma. Mesna at a dose of 1800 mg/m 2 is a component of this regimen and is infused on days -4, -3 and -2. LACE chemotherapy has been shown to be relatively well-tolerated in patients treated for lymphoma. In one trial significant incidences of grades III-IV toxicity were not observed. The incidence of grades III-IV mucositis was reported as 8% while the incidence of non-haematological toxicities was reported as 9%. These results are comparable to other conditioning regimens of similar intensity. 12 However, there are few comparative studies looking at the safety of LACE chemotherapy in patients with HIV who are treated for lymphoma. This report describes a case of ASCT in a patient with HIV on ART therapy.
A 55-year-old man was admitted for LACE ASCT for anaplastic large cell non-Hodgkin lymphoma (NHL). ). This resulted in delayed count recovery and was followed by two cycles of CHOP after which the patient was diagnosed with doxorubicin-induced cardiotoxicity based on a decrease in left ventricular ejection fraction (LVEF) from 64% (baseline) to 51%. Subsequently, doxorubicin was omitted from the CHOP regimen and replaced with a potentially less cardiotoxic anthracycline, 13 epirubicin 88 mg (50 mg/m 2 ). The patient then completed a further two cycles of this regimen. Other medical history included HIV (CD4 count 329 cells per/lL and suppressed VL for the last 10 years), reflux, hypertension, depression and being a current smoker. After a complete remission (CR) demonstrated on positron emission tomography (PET) scan and bone marrow biopsy, the decision was made to proceed to ASCT in order to consolidate treatment. Pre-transplant cytomegalovirus (CMV) status was reported to be immunoglobulin M positive but polymerase chain reaction (PCR) negative. Epstein-Barr virus (EBV) and hepatitis B virus (HBV) antigen/core were both PCR negative. Central nervous system disease was assessed to have been cleared 6 months prior. The patient had completed immunisation with flu vaccine, pneumococcal vaccine and hepatitis B vaccine. Eastern Cooperative Oncology Group (ECOG) performance status was assessed to be 0. The patient had successfully stopped smoking with the aid of a hospital smoking cessation counsellor.
The literature was analysed for evidence of use of full dose chemotherapy in the HIV setting and for the extent and significance of drug interactions with the patient's current ART. The majority of data were suggestive that the interactions between newer ART agents, such as dolutegravir and raltegravir, and chemotherapy were not significant for overall survival.
14 Overlapping toxicity profiles including additive neurotoxicity, cardiotoxicity and hepatotoxicity can be clinically significant with some drug combinations. 15 Additive myelotoxicity is a more frequent complication. Zidovudine can result in severe neutropenia and it can potentiate that of chemotherapy, hence this combination is generally avoided. 16 In addition, ART regimens containing potent cytochrome P-450 enzyme-inhibiting components, such as protease inhibitors, namely ritonavir, can potentially inhibit the metabolism of some chemotherapy agents, resulting in increased cytotoxic exposure, greater myelosuppression and CD4 count depression and are therefore best avoided under these circumstances. 17 Evidently, the patient's pre-existing ART with raltegravir 400 mg twice a day, emtricitabine 200 mg oral daily and tenofovir 300 mg oral daily was deemed to be one of the safer options 18 and the decision was made to continue this regimen and go ahead with the full dose conditioning regimen LACE. Treatmentrelated risks such as the possibility of prolonged CD4 decline, increased risk of opportunistic infections and the possible need for intensive care unit (ICU) admission were discussed with the patient. The risks of continuing with the current ART regimen were accepted by the patient and the team in favour of a greater benefit of faster haematopoietic recovery post-transplant. 8, 19 Plerixafor 16 mg (0.24 mg/kg) subcutaneously daily and filgrastim 600 mg (10 mg/kg) subcutaneously twice a day were used to mobilise an adequate yield of 2. ) IV days -4, -3, -2) conditioning regimen was administered as per approved protocol. Mesna 4000 mg (120% of cyclophosphamide dose) is a component of this regimen and was infused on days -4, -3 and -2. Anti-emetic regimen included aprepitant 165 mg orally and palonosetron 250 micrograms both given on days -7, -5 and -3, ondansetron 8 mg twice a day as needed and metoclopramide 10 mg three times a day as needed. Prophylactic anti-infectives included dapsone 100 mg orally daily, valaciclovir 500 mg orally twice a day and bacterial prophylaxis with ciprofloxacin 500 mg twice a day and fungal prophylaxis with fluconazole 400 mg orally daily was commenced at the onset of the neutropenic phase. CMV PCR was checked monthly for the first 6 months. As CMV PCR was negative, CMV prophylaxis was not required.
Education of all chemotherapy agents and supportive medications was carried out by the unit pharmacist and education nurse. Nutritional status was regularly assessed. The patient continued to mobilise well and had good engagement with the team throughout admission.
Post-transplant, the complication of culture-positive hypotensive neutropenic septicaemia with Enterobacter and Enterococcal developed on day 10. This required ICU admission for inotropic support. Per routine practice, filgrastim was not used post-transplant and the neutropenic sepsis was managed with antibiotics only.
While in ICU, toxin-positive Clostridium difficile colitis was an issue, as was newly diagnosed atrial fibrillation requiring amiodarone. Diminished oral intake was flagged and was addressed with parenteral nutrition. After a nadir of 0.0 9 10 9 /L, neutrophils recovered to 0.86 9 10 9 /L on day 16, indicating engraftment (Figure 1A) . No interruptions to ART therapy were made and the patient continued to receive oral medications throughout his hospital stay.
OUTCOME
Engraftment was successful, with neutrophils at >1.0 9 10 9 /L ( Figure 1A ) and all complications resolved by day 30 post-transplant. CD4 count dropped to 209 cells per/lL ( Figure 1B ) 30 days post-transplant; however, this was not clinically significant. The patient was discharged home and visited daily by nursing staff under the 'Hospital in the home' program and completed a 2 week course of teicoplanin 400 mg IV daily. Weekly outpatient follow-up included haematology and infectious diseases clinic review, with routine biochemical and haematological pathology monitoring. At 6 months follow-up, the CD4 count had recovered to 201.6 cells per/lL, VL was 19 copies/mL ( Figure 1C ), ECOG status remained at 0 and the patient had returned to part-time work. He continued to be reviewed by the bone marrow unit and the HIV physician at monthly intervals.
CONCLUSION
ASCT is an effective treatment option for AIDS-related lymphoma, especially for patients who have demonstrated response to ART. ASCT, with full-dose conditioning, can be performed while ART therapy continues, with no adverse impact on engraftment or HIV control. LACE chemotherapy is an effective conditioning regimen in this setting with low incidence of treatment-related toxicity.
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A ANC nadir at day 3 and recovery post-ASCT B CD4 count was slightly depressed at 6 months follow-up C Viral load remained suppressed throughout treatment course 
